Drug intelligence / Profile preview

bevacizumab + tecemotide

Development stage: Unknown
Lead developer: ECOG-ACRIN Cancer Research Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous, Subcutaneous

Overview

Combination therapy consisting of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) that inhibits angiogenesis, and tecemotide (L-BLP25), a MUC1 antigen-specific cancer immunotherapy vaccine. This combination was investigated for treatment of locally advanced non-squamous non-small cell lung cancer (LA-NSCLC) following chemoradiotherapy and consolidation chemotherapy.

Targets

MUC1 (Mucin-1 Antigen)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + tecemotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + tecemotide.

Explore the full profile